Atyr PHARMA INC (NASDAQ:ATYR) Director Jane A. Gross Buys 3,750 Shares of Stock

Atyr PHARMA INC (NASDAQ:ATYR) Director Jane A. Gross bought 3,750 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $4.00 per share, with a total value of $15,000.00. Following the completion of the transaction, the director now owns 9,750 shares of the company’s stock, valued at $39,000. This represents a 62.50 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Atyr PHARMA Stock Up 1.0 %

Atyr PHARMA stock opened at $4.01 on Tuesday. Atyr PHARMA INC has a fifty-two week low of $1.42 and a fifty-two week high of $4.66. The stock has a market cap of $336.61 million, a PE ratio of -4.27 and a beta of 0.98. The firm’s 50-day simple moving average is $3.65 and its 200 day simple moving average is $3.09. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. Research analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Friday. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating for the company. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Atyr PHARMA has a consensus rating of “Buy” and an average target price of $18.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. purchased a new position in Atyr PHARMA in the fourth quarter valued at about $201,000. Alpine Global Management LLC purchased a new position in Atyr PHARMA in the fourth quarter valued at about $63,000. Woodline Partners LP purchased a new position in Atyr PHARMA in the fourth quarter valued at about $6,092,000. Squarepoint Ops LLC purchased a new position in Atyr PHARMA in the fourth quarter valued at about $96,000. Finally, Two Sigma Advisers LP purchased a new position in Atyr PHARMA in the fourth quarter valued at about $44,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.